Prior SARS-CoV-2 infection ups protection for vaccinated
Nov 15, 2021
Prior infection was linked to a lower risk for breakthrough infection among individuals vaccinated with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).
Risk for VTE up for IBD patients infected with SARS-CoV-2
Jun 24, 2021
The odds of VTE increased 8.15-fold according to models adjusting for recent hospitalization and steroid exposure.
FDA approves Rinvoq for treatment of atopic Dermatitis
Jan 19, 2022
Serious side effects of Rinvoq include infections such as tuberculosis, a greater risk for death in people ages 50 years and older who have at least one cardiovascular risk factor, an increased risk for...
FDA approves first breath test for COVID-19
Apr 15, 2022
The test, which must be administered by a trained operator, demonstrates a high degree of accuracy.
NIH spending nearly $470 million on ‘long-haul COVID’ study
Sep 16, 2021
The goal is to uncover why some people have prolonged symptoms or develop new or returning symptoms after recovering from COVID-19.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.
Adverse effects generally mild after BNT162b2 mRNA booster in over 60s
Apr 18, 2022
Thirty percent of those aged 60 years or older receiving a booster reported at least one adverse event; few sought medical attention.
Sleep problems linked to increased risk for stroke
Apr 06, 2023
The odds of stroke increased with short or long duration of sleep, impaired sleep quality, snoring, snorting and breathing cessation.
FDA approves topical treatment for molluscum contagiosum
Jul 24, 2023
Ycanth has been approved for adults and children older than 2 years.
Pfizer-BioNTech COVID-19 vaccine receives full FDA approval
Aug 23, 2021
The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older.